The objective of this study is to compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU).
Signed a valid, IRB/EC-approved informed consent form.
You may not be if
Meets any contraindications per locally applicable Instructions for Use (IFU).
